Nasus Pharma CFO Eyal Rubin to exit; finance director Oren Elmaliach named interim CFO
NSRX•Interim CFO appointed
Director of Finance Oren Elmaliach was appointed interim CFO.
Elmaliach has been with Nasus since inception; a CPA with 15+ years’ finance experience across public and private life sciences companies.
CFO transition announced
Nasus Pharma CFO Eyal Rubin will leave to pursue an opportunity outside the life sciences industry.
Rubin will remain through Sept. 18, 2026 to support an orderly transition.
Related News
Ciena Corporation <CIEN.N>: Northland Capital Raises to Outperform From Market Perform; Raises Target Price to $500 From $450
CIEN•
Rubrik, Inc. <RBRK.N>: Mizuho raises target price to $112 from $90
RBRK•
